Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Lilly notified Adocia of termination on January 26, 2017, returning all licensed rights at no cost despite BioChaperone Lispro showing 'significant improvement…
Adocia's claim escalated to $1.8B; Lilly countersued for $188M alleging Adocia concealed discoveries. The article framed the relationship as deteriorating into…
Arbitration panel awarded Adocia just $11.6M against its $1.8B claim, decisively in Lilly's favor; Adocia CEO Gérard Soula said Adocia was 'surprised and…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Eli Lilly licensed worldwide rights to Adocia's BioChaperone Lispro ultra-rapid insulin for $50M upfront plus up to $280M in development milestones, $240M in sales milestones and tiered royalties. Lilly later terminated the alliance in 2017, triggering a multi-year arbitration ultimately decided in Lilly's favor.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Adocia SA (this deal) | 2014 | $570M | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2014 deals · Eli Lilly and Company deals · Metabolic deals